CN114667142A - 治疗肝脏病症 - Google Patents

治疗肝脏病症 Download PDF

Info

Publication number
CN114667142A
CN114667142A CN202080077929.8A CN202080077929A CN114667142A CN 114667142 A CN114667142 A CN 114667142A CN 202080077929 A CN202080077929 A CN 202080077929A CN 114667142 A CN114667142 A CN 114667142A
Authority
CN
China
Prior art keywords
compound
liver
patient
formula
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080077929.8A
Other languages
English (en)
Chinese (zh)
Inventor
M·费诺
王宇锦
W·钟
K·克鲁谢尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tuozhen Pharmaceutical Co
Original Assignee
Tuozhen Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tuozhen Pharmaceutical Co filed Critical Tuozhen Pharmaceutical Co
Publication of CN114667142A publication Critical patent/CN114667142A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202080077929.8A 2019-11-08 2020-11-06 治疗肝脏病症 Pending CN114667142A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962933277P 2019-11-08 2019-11-08
US62/933,277 2019-11-08
US202063004403P 2020-04-02 2020-04-02
US63/004,403 2020-04-02
PCT/US2020/059522 WO2021092474A1 (en) 2019-11-08 2020-11-06 Treating liver disorders

Publications (1)

Publication Number Publication Date
CN114667142A true CN114667142A (zh) 2022-06-24

Family

ID=75849579

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080077929.8A Pending CN114667142A (zh) 2019-11-08 2020-11-06 治疗肝脏病症

Country Status (11)

Country Link
EP (1) EP4054567A4 (enExample)
JP (1) JP2023501386A (enExample)
KR (1) KR20220098168A (enExample)
CN (1) CN114667142A (enExample)
AU (1) AU2020380968A1 (enExample)
BR (1) BR112022008639A2 (enExample)
CA (1) CA3160445A1 (enExample)
CL (1) CL2022001167A1 (enExample)
IL (1) IL292459A (enExample)
MX (1) MX2022005407A (enExample)
WO (1) WO2021092474A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025185730A1 (zh) * 2024-03-08 2025-09-12 上海拓界生物医药科技有限公司 靶向INHBE的RNAi剂

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4259279A1 (en) 2020-12-14 2023-10-18 Regeneron Pharmaceuticals, Inc. Methods of treating metabolic disorders and cardiovascular disease with inhibin subunit beta e (inhbe) inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101743232A (zh) * 2007-07-16 2010-06-16 伊莱利利公司 调节fxr的化合物和方法
WO2018170173A1 (en) * 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
CN109152840A (zh) * 2016-03-28 2019-01-04 英特塞普特医药品公司 通过结合fxr激动剂和arb获得的药物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140187633A1 (en) * 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US20210121493A1 (en) * 2017-07-25 2021-04-29 Cedars-Sinai Medical Center Methods for treating liver diseases
EP3844156A4 (en) * 2018-08-30 2022-06-08 Terns Pharmaceuticals, Inc. TREATMENT OF LIVER DISEASES

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101743232A (zh) * 2007-07-16 2010-06-16 伊莱利利公司 调节fxr的化合物和方法
CN109152840A (zh) * 2016-03-28 2019-01-04 英特塞普特医药品公司 通过结合fxr激动剂和arb获得的药物
WO2018170173A1 (en) * 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
US20200131129A1 (en) * 2017-03-15 2020-04-30 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MICHAEL J.GENIN 等: "Discovery of 6-(4-{[5-Cyclopropyl-3-(2, 6-dichlorophenyl)isoxazol-4-yl]methoxy}piperidin-1 -yl)-1-methyl-1H-indole-3-carboxylic Acid: A Novel FXR Agonist for the Treatment of Dyslipidemia", 《JOURNAL OF MEDICINAL CHEMISTRY》, vol. 58, no. 24, pages 9768 - 9772, XP055932709, DOI: 10.1021/acs.jmedchem.5b01161 *
隋常琪 等: "FXR在肝脏疾病中的作用及其激动剂的研究进展", 《天津药学》, vol. 31, no. 1, pages 49 - 54 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025185730A1 (zh) * 2024-03-08 2025-09-12 上海拓界生物医药科技有限公司 靶向INHBE的RNAi剂

Also Published As

Publication number Publication date
MX2022005407A (es) 2022-05-24
CL2022001167A1 (es) 2023-02-10
BR112022008639A2 (pt) 2022-07-19
WO2021092474A1 (en) 2021-05-14
IL292459A (en) 2022-06-01
CA3160445A1 (en) 2021-05-14
EP4054567A4 (en) 2024-01-10
KR20220098168A (ko) 2022-07-11
EP4054567A1 (en) 2022-09-14
AU2020380968A1 (en) 2022-05-12
JP2023501386A (ja) 2023-01-18

Similar Documents

Publication Publication Date Title
US20240316025A1 (en) Combination treatment of liver disorders
EP4149453A1 (en) Combination treatment of liver disorders
US20230241071A1 (en) Combination treatment of liver disorders
Davis Cholestasis and endogenous opioids: liver disease and exogenous opioid pharmacokinetics
US20250099468A1 (en) Treating liver disorders with an ssao inhibitor
JP2018076332A (ja) （３ａＲ）−１，３ａ，８−トリメチル−１，２，３，３ａ，８，８ａ−ヘキサヒドロピロロ［２，３−ｂ］インドール−５−イルフェニルカルバメートの有効量およびその使用方法
KR20180051561A (ko) 특정 환자 집단에서 신경퇴행성 장애를 치료하는 방법
US20090093509A1 (en) Methods and Compositions for the Treatment of Pruritus
EP3398599A1 (en) Compositions and methods for prophylaxis and treatment of addictions
AU2020380968A1 (en) Treating liver disorders
EP4166137B1 (en) Therapeutic agent for fatty liver disease
US20220387414A1 (en) Treating liver disorders
HK40089150A (en) Therapeutic agent for fatty liver disease
HK40089150B (en) Therapeutic agent for fatty liver disease
Haddley Lu-AA-21004

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220624